Characteristics of viral pneumonia in the COVID-19 era: an updateReview Published on 2021-03-292023-06-14 Journal: Infection [Category] MERS, [키워드] heparin neuraminidase inhibitor Remdesivir SARS-CoV-2 Steroids Viral pneumonia [DOI] 10.1007/s15010-021-01603-y PMC 바로가기 [Article Type] Review
Association of Neutrophil Activation, More Than Platelet Activation, With Thrombotic Complications in Coronavirus Disease 20192019년 코로나바이러스 질병의 혈전 합병증과 함께 혈소판 활성화 이상의 호중구 활성화 연관성Article Published on 2021-03-292022-09-11 Journal: The Journal of Infectious Diseases [Category] SARS, 바이오마커, [키워드] activated activating acute respiratory syndrome age analyzed Antithrombotic Aspirin association Biomarker Biomarkers blocked Complication coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 disease severity enzyme feature healthy control help heparin hospitalized patients hypercoagulability Infection inhibiting less leukocyte leukocyte activation leukocytes low-molecular weight heparin matrix metalloproteinase matrix metalloproteinase-9 (MMP-9) NET NETs neutrophil neutrophil activation Neutrophil extracellular trap Neutrophil extracellular traps neutrophil extracellular traps (NETs) Neutrophils normalized Patient patients with COVID-19 plasma Platelet platelet activation Platelets predict respiratory SARS-CoV-2 Severe acute respiratory syndrome significantly increased thrombosis Treatment triggered Venous Thromboembolism venous thromboembolism (VTE) VTE were measured worsening [DOI] 10.1093/infdis/jiaa756 PMC 바로가기 [Article Type] Article
The relationship between cardiac injury, inflammation and coagulation in predicting COVID-19 outcomeCOVID-19 결과 예측에서 심장 손상, 염증 및 응고 사이의 관계Article Published on 2021-03-222022-09-01 Journal: Scientific Reports [Category] SARS, 바이오마커, 진단, [키워드] abnormality adverse outcome anticoagulation treatment association attenuate attenuation benefit change Coagulation Coagulopathy Complication confounders consecutive patient coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 mortality CRP D-dimer determinant Effect Endpoint enrolled greater heparin Hospitalized In-hospital individuals Inflammation Inflammatory Inflammatory response Injury low molecular weight low molecular weight heparin mechanism Mortality observational study outcome PaO pathway Pneumonia Predictive markers primary endpoint Prognostic markers risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pneumonia sensitivity severity single-center subject therapy Treatment troponin T [DOI] 10.1038/s41598-021-85646-z PMC 바로가기 [Article Type] Article
Predictors of infection, symptoms development, and mortality in people with SARS-CoV-2 living in retirement nursing homes은퇴 요양원에 거주하는 SARS-CoV-2 감염자의 감염, 증상 발생 및 사망률 예측인자Research Article Published on 2021-03-162022-09-12 Journal: PLoS ONE [Category] MERS, SARS, 진단, [키워드] age Analysis Angiotensin II blocker chi-square test chronic chronic obstructive pulmonary disease Clinical data collected conducted correlated Cox proportional-hazards model death deaths dependent variable develop died Dyspnea enrolled evaluate evidenced Factor Fever foci Gender heparin high mortality hypokinetic disease increased risk Infection lower mortality risk lower risk male malignancies management Mental Disorders Mortality multivariate analyses Multivariate analysis neurological nursing homes Obstructive obstructive pulmonary disease pandemic Pearson Pearson chi-square test predictor predictors pulmonary disease receptor Retrospective study risk SARS-CoV-2 SARS-COV-2 infection Significant Spread Student’s t-test subjects Swab Symptom Symptoms syndrome Treatment variable was used with infection [DOI] 10.1371/journal.pone.0248009 PMC 바로가기 [Article Type] Research Article
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG – RAPID Trial): A structured summary of a study protocol for a randomised controlled trial입원한 COVID-19의 응고병증: COVID-19 유행병에 대한 신속한 대응으로서 치료용 항응고제 대 표준 치료의 실용적인 무작위 통제 시험(RAPID COVID COAG – RAPID 실험): 무작위 통제 실험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-03-102022-09-10 Journal: Trials [Category] SARS, 임상, 치료기술, [키워드] 1:1 absence acutely ill hospitalized medical patients Admission age allergy allocation concealment allocation sequence Alpha America and protocol Anticoagulant anticoagulation antiplatelet antithrombotic therapy apixaban arterial bleeding bleeding risk Blinding block sizes blood cell Brazil can not Canada Care Chain Reaction changed choice clinical trial clinically clinician Coagulation Coagulopathy Committee complex Composite computer-generated contraindication control group Controlled COVID COVID-19 Critical Critical illness cryoprecipitate D-dimer D-dimer value Dabigatran dalteparin Date death defined dependent on detect determine diagnosis of SARS-CoV-2 diagnostic Diagnostic imaging discretion disorder dissemination dose dual edoxaban electrocardiogram element elevated emergency room enoxaparin Enrollment evaluated exclusion criteria expected experimental group fibrinogen fondaparinux frozen plasma Health Organization hemoglobin heparin heparin-induced thrombocytopenia High dose high risk hospital Hospital admission hospitalised Hospitalized hospitalized patient hospitalized patients ICU ICU admission include inclusion criteria indicated individual inflammatory biomarkers Informed consent INR intensive care intensive care unit Interactive Web Response System intermediate dose Invasive mechanical ventilation involved Ireland isothermal amplification judgement limit LMWH Local low molecular weight low molecular weight heparin Major major bleeding mechanical ventilation Non-invasive non-invasive positive pressure ventilation nucleic acid number objective occur Open-label open-label trial outcome oxygen oxygen saturation participant Patient patients Phase 3 plasma Platelet Platelet count Platelets polymerase chain polymerase chain reaction positive pressure positive pressure ventilation power Pregnancy pressure ventilation protocol random random allocation randomised randomised controlled trial randomization Randomized controlled trial Rapid recruited red blood cell renal replacement therapy replacement therapy response responsible reverse transcriptase Reverse transcriptase polymerase chain reaction risk risk difference rivaroxaban room air Sample size Saudi Arabia secondary Secondary outcomes Standard standard care status stratified study population Study protocol supplementary material symptomatic the patient the United State therapeutic anticoagulation therapeutic dose therapy thrombocytopenia Thromboembolism Thromboprophylaxis tinzaparin transcriptase transfusion treated Trial Trial registration two-sided ULN unfractionated heparin United Arab Emirates United States Venous Thromboembolism Ventilator-free days Version Warfarin website World Health Organization [DOI] 10.1186/s13063-021-05076-0 PMC 바로가기 [Article Type] Letter
Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral AnticoagulantsReview Published on 2021-03-072022-10-28 Journal: Biomedicines [Category] COVID-19, [키워드] activated activated partial thromboplastin time addition antagonist Anticoagulant anticoagulant drug anticoagulant effect anticoagulation bleeding Clinical use coronavirus disease COVID-19 Direct direct oral anticoagulants Diseases DOAC DOACs dose drug drugs effective Effects hemorrhage heparin International mechanism monitoring normalized Older oral oral anticoagulant Patient patients with COVID-19 Prevent Prothrombin time required risk Safe shown therapeutic therapy thromboembolic thrombosis treat Vitamin Warfarin [DOI] 10.3390/biomedicines9030264 PMC 바로가기 [Article Type] Review
Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study혈전 예방에도 불구하고 대규모 COVID-19 환자 집단의 전신 혈전증: 후향적 연구Article Published on 2021-03-012022-09-12 Journal: Thrombosis research [Category] SARS, 진단, [키워드] affected Analysis characteristics of patient Compliance Controlled trial Coronavirus infections Course COVID-19 COVID-19 patient CRP decrease diagnosed disease Disseminated intravascular coagulation entire cohort event heparin Heparin, low-molecular-weight implementation independent Inflammatory large cohort Mortality Most patient Non-survivors outbreak outcome parameters Patient patients poor prognosis protocol reported Retrospective study significantly significantly higher Spanish subgroup of patient suffered survivor systemic Thrombophilia Thromboprophylaxis thrombosis thrombotic thrombotic event Thrombotic events Treatment university venous Venous Thromboembolism [DOI] 10.1016/j.thromres.2020.12.024 PMC 바로가기 [Article Type] Article
Aminotransferases disorders associated with venous thromboembolic events in patients infected with COVID-19COVID-19에 감염된 환자의 정맥 혈전색전증과 관련된 아미노전이효소 장애Article Published on 2021-03-012022-09-11 Journal: Annals of hepatology [Category] MERS, SARS, 바이오마커, [키워드] Admission Aminotransferase Aminotransferases disorders analyzed Anticoagulant AST balance collected Comorbidities Comorbidity COVID-19 COVID-19 infection COVID-19 pandemic curative Day demographics Direct Direct oral anticoagulant disorder disorders distance DOAC DOACs eight elevated Elevated AST and ALT enoxaparin evaluate event Evidence Follow-up heparin incidence infected patient infected patients infected with COVID-19 laboratory parameter Laboratory parameters liver Liver disorders low molecular weight low molecular weight heparin lower limb lower limbs monitoring normalization outbreak Patient patients Perspective reported Retrospective study Thromboembolism treated venous thromboembolic Venous Thromboembolism VTE was performed [DOI] 10.1016/j.aohep.2020.10.002 PMC 바로가기 [Article Type] Article
The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptorCoronaviruses Published on 2021-02-272022-10-31 Journal: Emerging Microbes & Infections [Category] COVID-19, SARS, [키워드] ACE2 ACE2-expressing cell addition antagonized antiviral activity appear bind binding bovine Cell culture cell entry Coronavirus disease 2019 COVID-19 drug candidate effective experiment HCoV-229E HCoV-NL63 HCoV-OC43 heparan sulfate heparin host cell human coronavirus in vitro infect Interaction lack lactoferrin local concentration mechanism of action N-terminal pandemic plasma membrane Proteoglycan recent Remdesivir SARS-CoV-2 SARS-CoV-2 cell shown subsequent synergistic therapeutic interventions therapy viral replication viral spike protein [DOI] 10.1080/22221751.2021.1888660 PMC 바로가기 [Article Type] Coronaviruses
To Curb the Progression of Fatal COVID-19 Course—Dream or RealityArticle Published on 2021-02-272023-06-18 Journal: Current hypertension reports [Category] MERS, [키워드] ACEi/ARB COVID-19 glycocalyx heparin spironolactone [DOI] 10.1007/s11906-021-01130-z PMC 바로가기